William Blair upbeat on Lantheus Holdings' radiopharmaceutical opportunity

Lantheus Holdings

29/09/2023 15:12

** William Blair initiates coverage on Lantheus Holdings
 LNTH.O  with 'outperform' rating as it expects near and
long-term growth opportunities from the co's
radiopharmaceuticals business
    ** Brokerage sees a $15 bln opportunity in U.S. oncology
markets served by radiopharmaceuticals 
    ** Co recorded ~$211 million from its radiopharmaceutical
oncology business in Q2, driven by sales of its Pylarify
injection used for diagnosis of prostate cancer
    ** William Blair estimates Pylarify's total current
addressable market in prostate cancer to be around $1.6 billion
    ** Brokerage also sees co's mid-to-long term growth
potential in therapeutic uses of radiopharmaceutical candidates
PNT2002 and PNT2003, which it gained access to through its
licensing deal with POINT Biopharma Global  PNT.O  last year
    ** All nine brokerages covering LNTH rate the stock "buy" or
higher; median PT is $119.50 - LSEG
    ** LNTH shares down 1% in early trade at $68.78 but up 34%
YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;))